Tecmar

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Deafness, CDMO, Obesity, Syndrome, Infertility, Entrepreneurship, Disease, Diabetes, Ciliopathy, Patient, CRL, DNA, Display resolution, Kidney disease, GMP, Tecmar, Therapy, Paratriathlon, BBS, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Medical Devices, Genetics, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Medical school, B cell, CDMO, NUS, CRL, DNA, Tecmar, HQ, National university, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.
  • NUS Medicine will leverage this collaboration to access Charles River’s center of excellence, and established manufacturing platform, eXpDNA™.
  • In recent years, Charles River has significantly expanded its cell and gene therapy portfolio to streamline complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept to cure” advanced therapeutic solution.

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Tuesday, January 16, 2024
Health, Medical Devices, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Miami Beach Convention Center, Senior, CRL, CMC, Regulation, Patient, CTA, LVV, DNA, AAV, Education minister, GMP, Gene, Tecmar, IND, COA, Doctor of Philosophy, Investigational New Drug, RC2, Cell, CDMO, Commercialization, Plasmid, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.
  • Charles River will officially launch the off-the-shelf Rep/Cap plasmid offering during Advanced Therapies Week , January 16-19, at the Miami Beach Convention Center.
  • Join Dr. Baghirzade in the Gene Therapy Manufacturing Track as part of the Regulatory Alignment for Gene Therapy Manufacturing session to learn how to:
    Ensure alignment with phase-appropriate plasmid DNA, AAV, and lentiviral vector (LVV) manufacturing best practices
    Matthew Hewitt, B.A.
  • Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and capacity expansions to simplify complex supply chains and meet the growing global demand for plasmid DNA, viral vector, and cell therapy services.

Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Display resolution, Dystonia, NYSE, DNA, GMP, Hope, Entrepreneurship, Tecmar, Degenerative disease, CDMO, Patient, Hereditary spastic paraplegia, Visual impairment, Genetic testing, Muscle weakness, Spasticity, Golden, Seizure, Cerebellar ataxia, Partnership, CRL, Doctor of Philosophy, Parent, HQ, Life, DSM-IV codes, Intellectual disability, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing capabilities, Charles River offers a comprehensive “concept-to-cure” advanced therapies solution.
  • - Golden Whitrod, Tallulah Moon’s mother and Co-Founder and President, Genetic Cures for Kids, Inc.

Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids

Retrieved on: 
Tuesday, June 13, 2023
Research, Medical Devices, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, GMP, Associate Director of National Intelligence and Chief Information Officer, DNA, LVV, Plasmid, AAV, ATMP, CRL, NYSE, Tecmar, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.
  • Charles River’s off-the-shelf packaging plasmids offer an alternative solution to these hurdles with immediate availability, reduced development costs and simplified supply chains that streamline and secure lentiviral vector production.
  • In addition to its off-the-shelf offerings, Charles River provides services to meet customer specific needs such as regulatory requirements or product characteristics.
  • Combined with the Company’s legacy testing services, Charles River offers an industry-leading “concept-to-cure” solution for advanced therapies.

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

Retrieved on: 
Thursday, June 8, 2023
Neurology, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Clinical Trials, GMP, Seizure, Good, Associate Director of National Intelligence and Chief Information Officer, DNA, Infantile neuroaxonal dystrophy, Plasmid, Good manufacturing practice, Therapy, Hearing loss, Neurodegenerative disease, Cognate, Display resolution, Mutation, Research, Life expectancy, Doctor of Philosophy, PLAN, HQ, CDMO, Patient, INAD, Drug discovery, Diagnosis, CRL, PLA2G6, Nerve, NYSE, Tecmar, Disease, Pharmaceutical industry, Vaccine

The collaboration will leverage Charles River’s market leading contract development and manufacturing organization (CDMO) expertise in High Quality (HQ) plasmid DNA production, to manufacture its leading candidate for Phase I/II clinical trials.

Key Points: 
  • The collaboration will leverage Charles River’s market leading contract development and manufacturing organization (CDMO) expertise in High Quality (HQ) plasmid DNA production, to manufacture its leading candidate for Phase I/II clinical trials.
  • Plasmid DNA is a critical starting material for many cell and gene therapy therapeutics and demand continues to outstrip supply.
  • In response to this, Charles River recently announced the opening of a state-of-the-art HQ plasmid manufacturing center of excellence to address these supply shortages and support the growing needs of the cell and gene therapy field.
  • Their invaluable expertise will undoubtedly contribute to the advancement of our gene therapy program.” - Leena Panwala, Founder & Executive Director at INADcure.

Evident Acquired by Bain Capital: Partnership to Accelerate Future Growth and Innovation

Retrieved on: 
Monday, April 3, 2023
Evidence, Capital, Olympus, Olympus Corporation, History, Tecmar, Bain Capital, Renewable energy, Management

TOKYO, April 03, 2023 (GLOBE NEWSWIRE) -- Evident Corporation (“Evident”) announced today that it has been acquired by private equity firm Bain Capital Private Equity (“Bain Capital”) from Olympus Corporation (“Olympus”) pursuant to the definitive agreement signed on August 29, 2022.

Key Points: 
  • TOKYO, April 03, 2023 (GLOBE NEWSWIRE) -- Evident Corporation (“Evident”) announced today that it has been acquired by private equity firm Bain Capital Private Equity (“Bain Capital”) from Olympus Corporation (“Olympus”) pursuant to the definitive agreement signed on August 29, 2022.
  • Evident was newly established on April 1, 2022 as a wholly owned subsidiary of Olympus comprising the former Scientific Solutions business conducted by Olympus.
  • Headquartered in Tokyo, Japan, Evident conducts business in 24 countries worldwide with more than 4,300 employees.
  • Supported by Bain Capital, Evident will attain a higher level of agility and faster decision-making to drive innovation-based growth in the life science and industrial markets.

Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Thursday, March 9, 2023
Health, Medical Devices, General Health, Research, Science, Pharmaceutical, Biotechnology, Role, ATMP, Associate Director of National Intelligence and Chief Information Officer, Education minister, CDMO, HQ, GEN, DNA, RG, Patient, AAV, History, GMP, Congress, Doctor of Philosophy, European Spatial Development Perspective, Plasmid, Tecmar, Vaccine, Pharmaceutical industry

Alongside a wealth of expert speakers and panel discussions, Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services will present: The Role of Plasmid DNA in Expediting Gene Therapy Manufacturing and Beyond.

Key Points: 
  • Alongside a wealth of expert speakers and panel discussions, Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services will present: The Role of Plasmid DNA in Expediting Gene Therapy Manufacturing and Beyond.
  • The addition of pHelper plasmids follows the launch of the eXpDNA™ plasmid manufacturing platform , established over decades of plasmid DNA CDMO scale-up experience, which significantly reduces plasmid production turnaround time for advanced therapy medical product (ATMP) and vaccine developers.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and recent expansions to simplify complex supply chains and meet growing global demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing services, Charles River offers an industry-leading “concept-to-cure” solution for advanced therapies.